Navigation Links
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Date:12/15/2009

n Medicines Agency by the end of the second quarter in 2010.

About Diabetes

Diabetes affects more than 24 million people in the U.S., and it is estimated that by 2010, it will affect 284.6 million adults worldwide.(i, ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the U.S. and costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi, vii)

About BYETTA® (exenatide) injection

BYETTA is the first and only FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
2. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
3. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
4. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
5. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
6. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
7. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
8. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
9. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
10. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
11. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... DUBLIN , Apr. 24, 2015 /PRNewswire/ ... ) has announced the addition of the ... Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & ... Institute) - Global Forecast to 2020" ... global laboratory accessories market is expected to ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... Nov. 22, 2011 Cadence Pharmaceuticals, Inc. (Nasdaq: ... previously announced public offering of 21,800,000 shares of its ... full exercise of an over-allotment option previously granted to ... per share.  The net proceeds from the offering, after ...
... Nov. 22, 2011  Medical Science Liaisons are the ... in the marketplace. Biopharmaceutical and medical device companies ... services to a diverse set of customers that ... opinion leaders, payer and government thought leaders, and ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters 2Delivering Exceptional Medical Science Liaison Services to Key Stakeholders in the Marketplace 2
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
(Date:4/25/2015)... April 25, 2015 By definition, a CIO’s ... for the enterprise relying on their judgement and expertise to ... But according to an article published in National Mortgage ... actually be doing a disservice to their responsibilities by focusing ... and t’s are crossed when it comes to company policy ...
(Date:4/25/2015)... April 25, 2015 Parker and Sons projects ... cooling, has spiked in Arizona alongside the growing economy. As ... forty employees for April to help account for the rising ... employees in April is something we are enthusiastic about. It ... Paul Kelly, president at Parker and Sons. , Indeed, Parker ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day ... in the nation! This year, on May 5th, 2015, Secura ... take DI Day on the road by supporting the first ... RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants and ... change by stating, "The first Twin Cities DI Day was ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
... , WASHINGTON, Sept. 9 As Obama prepares to ... League challenged the nation,s Catholic bishops to be prepared to shut ... this action to compromising with the intrinsic evils currently contained in ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) , , ...
... , BOSTON, Sept. 9 A ... a result of laboratory use and confinement. Developmental Context ... published in the September issue, Vol. 45 (5), of the ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) ...
... ... Child Safety , ... (PRWEB) September 9, 2009 -- September sees more than 500,000 children head back to school ... do parents keep their kids safe when they are in someone else’s care? , , ...
... CITY, Calif., Sept. 9 Abaxis, Inc. (Nasdaq: ABAX ... today that Clint Severson, chairman and chief executive officer, will present ... Thursday, September 17, 2009 at 10:00 a.m. ET. The conference will ... City. , , About Abaxis ...
... Fla., Sept. 9 Workforce Prescriptions ("WRX") announced on Tuesday the ... national quality award, funded by a private endowment, developed to honor ... foster efficient labor practices without resorting to workforce reductions or dramatic ... easy thing to make the paradigm shift in understanding required to ...
... The following is a heartfelt opinion piece about the ... Carise for the Phoenix House blog. A ... adjunct clinical professor at the University of Pennsylvania and director of ... perspective of a leading substance abuse treatment and research professional - ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3Health News:Keeping Kids Safe Through Education 2Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 2Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 3Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 4
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: